Johnson & Johnson Stock News

Atlas Private Wealth Advisors grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,191 shares of the companys stock after buying an additional 421 shares during the period. Johnson & Johnson accounts []

First Quadrant L P CA raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,458 shares of the companys stock after purchasing an additional 145 shares during the period. []

Armstrong Henry H Associates Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 0.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 423,717 shares of the companys stock after selling 1,194 shares during the period. Johnson & Johnson comprises about 7.9% of []

Calamos Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 7.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 731,080 shares of the companys stock after acquiring an additional 48,943 shares during the period. Calamos Advisors LLCs holdings []

Moreno Evelyn V lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% in the third quarter, HoldingsChannel.com reports. The firm owned 3,767 shares of the companys stock after selling 180 shares during the quarter. Moreno Evelyn Vs holdings in Johnson & Johnson were worth $609,000 as of its most recent SEC filing. []

Johnson & Johnson (NYSE:JNJ) CAO Robert J. Decker sold 5,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, December 7th. The shares were sold at an average price of $163.21, for a total transaction of $816,050.00. The sale was disclosed in a filing with the SEC, which is available at []

Krilogy Financial LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 6.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 9,286 shares of the companys stock after acquiring an additional 599 shares during the period. Krilogy Financial LLCs holdings in Johnson & Johnson were worth $1,500,000 at the end of the most []

Highland Capital Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 104,806 shares of the companys stock after selling 1,505 shares during the quarter. Johnson & Johnson accounts for approximately 1.0% of []

S. R. Schill & Associates lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,707 shares of the companys stock after selling 840 shares during the period. Johnson & []

RPG Investment Advisory LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,101 shares of the companys stock after selling 320 shares during the quarter. RPG Investment Advisory LLCs holdings in Johnson []

Rockland Trust Co. raised its position in Johnson & Johnson (NYSE:JNJ) by 1.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 204,675 shares of the companys stock after purchasing an additional 3,296 shares during the quarter. Johnson & Johnson comprises approximately 2.3% of Rockland []

BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for daratumumab in combination with lenalidomide and dexamethasone (Rd).1,2 Updated data from the randomised Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patie

Atlas Private Wealth Management lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,575 shares of the companys stock after selling 95 shares during the quarter. Johnson & Johnson comprises about 1.5% []

Cardan Capital Partners LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,421 shares of the companys stock after acquiring an additional 105 shares during the quarter. Cardan Capital Partners LLCs []